Baird Medical Targets US Clinicians with Minimally Invasive Thyroid Tech at Key Conferences

Event summary

  • Baird Medical (BDMD) will showcase its minimally invasive thyroid solutions at three US clinical conferences in Q1 2026.
  • The company aims to drive adoption of its needle-based therapies for benign thyroid nodules among US clinicians.
  • Baird Medical's technology is FDA 510(k)-certified and used in over 30 US hospitals, including Mayo Clinic and Columbia University Medical Center.
  • The company is the market leader in China for thyroid microwave ablation devices and consumables.

The big picture

Baird Medical's strategic focus on minimally invasive thyroid solutions aligns with the broader industry shift towards less invasive surgical options. The company's participation in key clinical conferences underscores its commitment to building direct relationships with the clinical community, a critical factor in driving adoption and market growth. With a strong presence in over 30 US hospitals and leadership in China, Baird Medical is positioning itself as a global player in the minimally invasive medical device space.

What we're watching

Clinical Adoption
How Baird Medical's direct engagement with US clinicians at these conferences will accelerate adoption of its minimally invasive thyroid solutions.
Market Expansion
Whether Baird Medical can sustain its market leadership in China while expanding its presence in the US and over 20 other countries.
Regulatory Dynamics
The pace at which Baird Medical can navigate regulatory conditions and developments in both the US and international markets.